Advancing Bispecifics and Combination Therapy to the Clinic banner

Advancements in platform and technology developments for bispecific and multi-specific antibodies are leading to a profusion of new constructs and clinical candidates that are being vetted for their safety and efficacy in the clinic. A review of clinical and preclinical data will be featured at the 15th Annual Advancing Bispecifics and Combination Therapy to the Clinic: Novel and Synergistic Combinations, taking place 15 November 2023 in Lisbon, Portugal, at the 15th Annual PEGS Europe Summit. Industry leaders will be discussing translational approaches and optimization of candidates so they can advance them to the growing repertoire of successful bispecific antibody therapeutics that are FDA-approved and on the market.

Scientific Advisory Board: 
     Nicolas Fischer
, PhD, CEO, Light Chain Bioscience 
     Pieter Fokko van Loo, PhD, Senior Director, Oncology – Immunology, Merus NV 
     Jeanette H.W. Leusen, PhD, Professor, Translational Immunology, Utrecht University 
     Paul WH Parren, PhD, Executive Vice President and Head, Research and Development, LAVA Therapeutics; Professor,
     Molecular Immunology, Leiden University Medical Center
     David E. Szymkowski, PhD, Vice President, Preclinical Operations, Xencor, Inc.


Recommended Short Course*
Monday, 13 November, 14:00 – 17:00
SC2: Developability of Bispecific Antibodies: Formats and Applications
*Separate registration required. See short courses page for details. All short courses take place in-person only.

For more details on the conference, please contact:

Christina Lingham
Executive Director, Conferences and Fellow
Cambridge Healthtech Institute
Phone: (+1) 781-972-5464

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5452

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1340